{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:54:34Z","timestamp":1777456474592,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Breastfeeding Medicine"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Information about influences of vortioxetine on pregnant women and neonates during perinatal period is almost unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>The case was a 28-year-old Japanese woman in her first pregnancy, treated for depression with vortioxetine (20 mg daily) among other medications. At 36 weeks of gestation, she was admitted for premature rupture of the membranes and delivered a girl with no apparent congenital anomalies. Immediately after birth, the neonate required brief respiratory support due to her dyspnea and poor muscle tone. Her respiratory condition improved in 6 days after delivery, and she demonstrated normal developmental progress afterward. Maternal plasma and breast milk samples, collected 4 days postpartum, revealed vortioxetine concentrations of 11.4 ng\/mL and 9.3 ng\/mL, respectively. The calculated relative infant dose (RID) was estimated at 0.32%. After discharge from hospital, the infant presented no detectable drug-related adverse effects, with over 50% of nutrition derived from breastfeeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case showed minimal transfer of vortioxetine into breast milk, reflected in a low RID. The findings suggest limited neonatal exposure to the drug, with no adverse developmental effects observed in the infant. However, the case also indicated the potential for vortioxetine use during pregnancy to contribute to the onset of severe neonatal asphyxia. Further research is needed for a comprehensive understanding of its impact on neonatal health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/bfm.2024.0005","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:29:08Z","timestamp":1715315348000},"page":"659-662","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Vortioxetine Exposure During Pregnancy and Lactation: A Japanese Case Study of Neonatal Implications and Quantitative Milk and Plasma Analyses"],"prefix":"10.1177","volume":"19","author":[{"given":"Mio","family":"Kiribayashi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, KKR Tachikawa Hospital, Tachikawa, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-1898","authenticated-orcid":false,"given":"Tetsufumi","family":"Suda","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, KKR Tachikawa Hospital, Tachikawa, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."},{"name":"Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasumi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Kushiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0612-7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1103296"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0074"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcme.2021.08.001"},{"key":"e_1_3_4_6_2","unstructured":"Food and Drug Administration. Bioanalytical method validation; Guidance for industry. 2018. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf [Last accessed: accessed 5January 2024]."},{"key":"e_1_3_4_7_2","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use Guideline on bioanalytical method validation 21 July 2011. Available from: www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf [Last accessed: accessed 5January 2024]."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114236"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-6163.2004.00073.x"},{"key":"e_1_3_4_10_2","volume-title":"Hale\u2019s Medications & Mothers\u2019 Milk 2023: A Manual of Lactational Pharmacology","author":"Hale TW","year":"2023","unstructured":"Hale TW, , Krutsch K. Hale\u2019s Medications & Mothers\u2019 Milk 2023: A Manual of Lactational Pharmacology. Springer: New York, NY, 2023."},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12256"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000692"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25112483"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqz229"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091362"},{"issue":"1","key":"e_1_3_4_16_2","article-title":"Maternal exposure to antidepressants vilazodone and vortioxetine: Effects on neurodevelopment of young rat offspring","volume":"17","author":"Agrawal P","year":"2023","unstructured":"Agrawal P, , Singh P, , Singh KP. Maternal exposure to antidepressants vilazodone and vortioxetine: Effects on neurodevelopment of young rat offspring. Asian J Pharm, 2023; 17(1); doi: 10.22377\/ajp.v17i1.4720","journal-title":"Asian J Pharm"}],"container-title":["Breastfeeding Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/bfm.2024.0005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/bfm.2024.0005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/bfm.2024.0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:01:59Z","timestamp":1777381319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/bfm.2024.0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"alternative-id":["10.1089\/bfm.2024.0005"],"URL":"https:\/\/doi.org\/10.1089\/bfm.2024.0005","relation":{},"ISSN":["1556-8253","1556-8342"],"issn-type":[{"value":"1556-8253","type":"print"},{"value":"1556-8342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}